Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report
One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currentl...
Gespeichert in:
| Veröffentlicht in: | Urology (Ridgewood, N.J.) N.J.), 1987-12, Vol.30 (6), p.520-528 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 528 |
|---|---|
| container_issue | 6 |
| container_start_page | 520 |
| container_title | Urology (Ridgewood, N.J.) |
| container_volume | 30 |
| creator | Khanna, Om P. Son, Daniel L. Mazer, Howard Read, John Nugent, Dennis Cottone, Robert Heeg, Michael Rezvan, Masoud Viek, Nicholas Friedmann, Marvin |
| description | One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currently have follow-up. Of these, 54 were completely resected and 55 incompletely resected. For complete resections, based on recurrence rates per 100 patient months, both BCG (0.22) and ADR (0.91) worked well, although BCG had a slightly lower recurrence rate. However, for incomplete resections, BCG (0.20) had a markedly lower recurrence rate than ADR (2.52). Eighteen patients failed initial treatment, with either BCG or ADR. All have been placed on long-term therapy schedules. Of the 12 failures who currently have follow-up,11 (92 %) have either partially or completely responded with additional intravesical therapy. No patients in this study have yet required cystectomies. |
| doi_str_mv | 10.1016/0090-4295(87)90429-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77828837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0090429587904298</els_id><sourcerecordid>77828837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-79fade0ea45f691b4ebc1a534557005927be0f10b375254b91b8598e588a85943</originalsourceid><addsrcrecordid>eNp9kcFq3DAQhkVoSbdJ3yAFHUppD24k27KkHgpladNCQg5tz2IsjUFFtreSHFjy8pGzyx57moH55mf4hpArzj5xxrtrxjSr2lqLD0p-1Kx0lTojGy5qWWmtxQuyOSGvyOuU_jLGuq6T5-S8abhiSm_I469lh3Hw1kOgfQDnMFILky0lR4SMjvZ76qcc4QGTtysG1oewJLqFMGLOWN0sGP1E50jBRQ_j3vrpM71bQvYWp1yyUl7cc0wBRxpxN8d8SV4OEBK-OdYL8uf7t9_bH9Xt_c3P7dfbyjaqy5XUAzhkCK0YOs37FnvLQTStEJIxoWvZIxs46xspatH2BVFCKxRKQWna5oK8P-Tu4vxvwZTN6JPFEGDCeUlGSlUr1cgCtgfQxjmliIPZlWsh7g1nZnVuVqFmFWqUNM_OjSprb4_5Sz-iOy0dJZf5u-McUvE3xKLXpxMmu041Yj3zywHD4uLBYzTJeiyfcD6izcbN_v93PAEDY58u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77828837</pqid></control><display><type>article</type><title>Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Khanna, Om P. ; Son, Daniel L. ; Mazer, Howard ; Read, John ; Nugent, Dennis ; Cottone, Robert ; Heeg, Michael ; Rezvan, Masoud ; Viek, Nicholas ; Friedmann, Marvin</creator><creatorcontrib>Khanna, Om P. ; Son, Daniel L. ; Mazer, Howard ; Read, John ; Nugent, Dennis ; Cottone, Robert ; Heeg, Michael ; Rezvan, Masoud ; Viek, Nicholas ; Friedmann, Marvin</creatorcontrib><description>One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currently have follow-up. Of these, 54 were completely resected and 55 incompletely resected. For complete resections, based on recurrence rates per 100 patient months, both BCG (0.22) and ADR (0.91) worked well, although BCG had a slightly lower recurrence rate. However, for incomplete resections, BCG (0.20) had a markedly lower recurrence rate than ADR (2.52). Eighteen patients failed initial treatment, with either BCG or ADR. All have been placed on long-term therapy schedules. Of the 12 failures who currently have follow-up,11 (92 %) have either partially or completely responded with additional intravesical therapy. No patients in this study have yet required cystectomies.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/0090-4295(87)90429-8</identifier><identifier>PMID: 3318089</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Administration, Intravesical ; BCG Vaccine - therapeutic use ; Biological and medical sciences ; Carcinoma, Transitional Cell - therapy ; Clinical Trials as Topic ; Doxorubicin - therapeutic use ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Neoplasm Recurrence, Local - prevention & control ; Nephrology. Urinary tract diseases ; Remission Induction ; Time Factors ; Tumors of the urinary system ; Urinary Bladder Neoplasms - therapy ; Urinary tract. Prostate gland</subject><ispartof>Urology (Ridgewood, N.J.), 1987-12, Vol.30 (6), p.520-528</ispartof><rights>1987</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-79fade0ea45f691b4ebc1a534557005927be0f10b375254b91b8598e588a85943</citedby><cites>FETCH-LOGICAL-c386t-79fade0ea45f691b4ebc1a534557005927be0f10b375254b91b8598e588a85943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0090-4295(87)90429-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7668354$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3318089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khanna, Om P.</creatorcontrib><creatorcontrib>Son, Daniel L.</creatorcontrib><creatorcontrib>Mazer, Howard</creatorcontrib><creatorcontrib>Read, John</creatorcontrib><creatorcontrib>Nugent, Dennis</creatorcontrib><creatorcontrib>Cottone, Robert</creatorcontrib><creatorcontrib>Heeg, Michael</creatorcontrib><creatorcontrib>Rezvan, Masoud</creatorcontrib><creatorcontrib>Viek, Nicholas</creatorcontrib><creatorcontrib>Friedmann, Marvin</creatorcontrib><title>Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currently have follow-up. Of these, 54 were completely resected and 55 incompletely resected. For complete resections, based on recurrence rates per 100 patient months, both BCG (0.22) and ADR (0.91) worked well, although BCG had a slightly lower recurrence rate. However, for incomplete resections, BCG (0.20) had a markedly lower recurrence rate than ADR (2.52). Eighteen patients failed initial treatment, with either BCG or ADR. All have been placed on long-term therapy schedules. Of the 12 failures who currently have follow-up,11 (92 %) have either partially or completely responded with additional intravesical therapy. No patients in this study have yet required cystectomies.</description><subject>Administration, Intravesical</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Transitional Cell - therapy</subject><subject>Clinical Trials as Topic</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Remission Induction</subject><subject>Time Factors</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms - therapy</subject><subject>Urinary tract. Prostate gland</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFq3DAQhkVoSbdJ3yAFHUppD24k27KkHgpladNCQg5tz2IsjUFFtreSHFjy8pGzyx57moH55mf4hpArzj5xxrtrxjSr2lqLD0p-1Kx0lTojGy5qWWmtxQuyOSGvyOuU_jLGuq6T5-S8abhiSm_I469lh3Hw1kOgfQDnMFILky0lR4SMjvZ76qcc4QGTtysG1oewJLqFMGLOWN0sGP1E50jBRQ_j3vrpM71bQvYWp1yyUl7cc0wBRxpxN8d8SV4OEBK-OdYL8uf7t9_bH9Xt_c3P7dfbyjaqy5XUAzhkCK0YOs37FnvLQTStEJIxoWvZIxs46xspatH2BVFCKxRKQWna5oK8P-Tu4vxvwZTN6JPFEGDCeUlGSlUr1cgCtgfQxjmliIPZlWsh7g1nZnVuVqFmFWqUNM_OjSprb4_5Sz-iOy0dJZf5u-McUvE3xKLXpxMmu041Yj3zywHD4uLBYzTJeiyfcD6izcbN_v93PAEDY58u</recordid><startdate>19871201</startdate><enddate>19871201</enddate><creator>Khanna, Om P.</creator><creator>Son, Daniel L.</creator><creator>Mazer, Howard</creator><creator>Read, John</creator><creator>Nugent, Dennis</creator><creator>Cottone, Robert</creator><creator>Heeg, Michael</creator><creator>Rezvan, Masoud</creator><creator>Viek, Nicholas</creator><creator>Friedmann, Marvin</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19871201</creationdate><title>Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report</title><author>Khanna, Om P. ; Son, Daniel L. ; Mazer, Howard ; Read, John ; Nugent, Dennis ; Cottone, Robert ; Heeg, Michael ; Rezvan, Masoud ; Viek, Nicholas ; Friedmann, Marvin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-79fade0ea45f691b4ebc1a534557005927be0f10b375254b91b8598e588a85943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Administration, Intravesical</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Transitional Cell - therapy</topic><topic>Clinical Trials as Topic</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Remission Induction</topic><topic>Time Factors</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms - therapy</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khanna, Om P.</creatorcontrib><creatorcontrib>Son, Daniel L.</creatorcontrib><creatorcontrib>Mazer, Howard</creatorcontrib><creatorcontrib>Read, John</creatorcontrib><creatorcontrib>Nugent, Dennis</creatorcontrib><creatorcontrib>Cottone, Robert</creatorcontrib><creatorcontrib>Heeg, Michael</creatorcontrib><creatorcontrib>Rezvan, Masoud</creatorcontrib><creatorcontrib>Viek, Nicholas</creatorcontrib><creatorcontrib>Friedmann, Marvin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khanna, Om P.</au><au>Son, Daniel L.</au><au>Mazer, Howard</au><au>Read, John</au><au>Nugent, Dennis</au><au>Cottone, Robert</au><au>Heeg, Michael</au><au>Rezvan, Masoud</au><au>Viek, Nicholas</au><au>Friedmann, Marvin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>1987-12-01</date><risdate>1987</risdate><volume>30</volume><issue>6</issue><spage>520</spage><epage>528</epage><pages>520-528</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currently have follow-up. Of these, 54 were completely resected and 55 incompletely resected. For complete resections, based on recurrence rates per 100 patient months, both BCG (0.22) and ADR (0.91) worked well, although BCG had a slightly lower recurrence rate. However, for incomplete resections, BCG (0.20) had a markedly lower recurrence rate than ADR (2.52). Eighteen patients failed initial treatment, with either BCG or ADR. All have been placed on long-term therapy schedules. Of the 12 failures who currently have follow-up,11 (92 %) have either partially or completely responded with additional intravesical therapy. No patients in this study have yet required cystectomies.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3318089</pmid><doi>10.1016/0090-4295(87)90429-8</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-4295 |
| ispartof | Urology (Ridgewood, N.J.), 1987-12, Vol.30 (6), p.520-528 |
| issn | 0090-4295 1527-9995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77828837 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Intravesical BCG Vaccine - therapeutic use Biological and medical sciences Carcinoma, Transitional Cell - therapy Clinical Trials as Topic Doxorubicin - therapeutic use Female Follow-Up Studies Humans Male Medical sciences Neoplasm Recurrence, Local - prevention & control Nephrology. Urinary tract diseases Remission Induction Time Factors Tumors of the urinary system Urinary Bladder Neoplasms - therapy Urinary tract. Prostate gland |
| title | Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T18%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Superficial%20bladder%20cancer%20treated%20by%20intravesical%20bacillus%20Calmette-Guerin%20or%20adriamycin:%20Multicenter%20study%20interim%20report&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Khanna,%20Om%20P.&rft.date=1987-12-01&rft.volume=30&rft.issue=6&rft.spage=520&rft.epage=528&rft.pages=520-528&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/0090-4295(87)90429-8&rft_dat=%3Cproquest_cross%3E77828837%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77828837&rft_id=info:pmid/3318089&rft_els_id=0090429587904298&rfr_iscdi=true |